Read the NICE guidelines for using Selpercatinib in the treatment of advanced thyroid cancer with RET alterations

NICE have published a full report on the recommendations for using Selpercatinib in the treatment of advanced thyroid cancer with RET alterations. The Society for Endocrinology was a key stakeholder in the consideration and production of these important recommendations.

Read the report